Amplified P-wave duration predicts incident atrial fibrillation in the general population: Results from the Hamburg City Health Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Clinical risk factors identify subjects at risk of incident atrial fibrillation (AF) with only mediocre accuracy. Amplified P-wave duration (PWD) is a novel electrocardiographic marker for conduction delay in atrial cardiomyopathy, which in turn is associated with AF. Objective The aim of this study is to assess whether amplified PWD can predict incident AF in the general population. Methods Amplified PWD was assessed manually on a signal-modified electrocardiogram in 2,134 participants from the population-based Hamburg City Health Study. Incident AF during 5-year follow-up was defined as primary endpoint. Multivariable Cox regression models were constructed including significant clinical risk factors, ECG parameters and transthoracic echocardiography (TTE) parameters and the predictive power for the primary endpoint was evaluated. Results Over a median follow-up of 5.5 years, 102 participants (4.8%) developed incident AF. The upper tertile of amplified P-wave duration was the only significant ECG-derived predictor for incident AF (Hazard Ratio [ HR ]: 2.02; p =.010) in the multivariable ECG-based model, alongside age ( HR : 1.07; p =.013) and body mass index ( HR : 1.08; p =.003), after adjustment for significant clinical risk factors (C-index: 0.764). A comprehensive combined ECG/TTE model achieved a C-index of 0.770, with age ( HR : 1.07; p =.020) and left atrial volume ( HR : 1.02; p =.020) remaining significant predictors. Conclusion Amplified PWD as novel ECG-based marker predicts incident AF in a population-based cohort and may provide a pragmatic ECG-derived marker of atrial cardiomyopathy for risk assessment beyond conventional risk stratification.
Source: Heart Rhythm O2
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,150
Funders: Amgen Foundation, Amgen, Pfizer, AstraZeneca, Deutsches Krebsforschungszentrum, Joachim Herz Stiftung, Deutsches Zentrum für Herz-Kreislaufforschung, Abiomed, European Commission, Bundesministerium für Bildung und Forschung, Deutsche Gesetzliche Unfallversicherung, Deutsche Stiftung für Herzforschung, Deutsche Herzstiftung, Horizon 2020 Framework Programme, HORIZON EUROPE Framework Programme, European Research Council, Universitätsklinikum Hamburg-Eppendorf
Awards: Personalised pharmacometabolomic optimisation of treatment for hypertension, Juniorverbünde in der Systemmedizin: Molekulare Charakterisierung von Kandidatengenen und Signalwegen für das Vorhofflimmern sowie Untersuchungen zur Genetischen Epidemiologie (symAtrial), Universitätsklinkum Hamburg-Epppendorf, G1602671910, DIGITAL, RISK-BASED SCREENING FOR ATRIAL FIBRILLATION IN THE EUROPEAN COMMUNITY, G2472745146, G2683322055, G2844294282, Big Data 4 Better Hearts - Sofia ref.: 116074, An EU-Canada joint infrastructure for next-generation multi-Study Heart research, G5539059467, G6015547599, G6723475928, G6944966942, G7240805260, G754489119, ERACoSysMed3 - Verbundprojekt: PARIS - Personalisierte Vorhofflimmerrisikobestimmung für ischämischen Schlaganfall und Krankheitsverlauf - Projektion hin zu einem vereinheitlichten Machine Learning basierten klinischen Index, G8707897456
OpenAlex ID: W7148423970
